Efficacy Comparison of Two Kinds of Treatment in Treating Dry Eye Caused by Meibomian Gland Dysfunction

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02958514

Enrollment

Registered

2016-11-08

Start date

2016-11-30

Completion date

2017-03-31

Last updated

2022-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye Syndrome

Keywords

IPL, MGD

Brief summary

This study aims to evaluate the efficacy of intense pulsed light in treating dry eye caused by meibomian gland dysfunction and make a comparison between the traditional treatment.

Interventions

DEVICEintense pulsed light

Intense pulse light (IPL) has been used in dermatology practices for several years as a treatment for rosacea and acne.IPL uses Xenon flashlamp to emit wavelengths of light from 400 to 1200nm. When placed on the light, a filter restricts the wavelength to the visible light range of \*500nm.In 2007-2008, an IPL treatment technology-the Diamond Q4 by DermaMed Solutions-was specifically configured to our specifications with the goal of stimulating secretion of normal meibum via skin treatment effects on the meibomian glands. It was discovered that dry eye patients are better positioned for gland expression, as IPL seems to liquefy the abnormal viscous meibum and dilate the glands.

DRUGTobramycin and Dexamethasone Ophthalmic Ointment

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

26 Years to 78 Years

Healthy volunteers

Inclusion criteria

* patients with dry eye syndrome and diagnosed as MGD

Exclusion criteria

* an infection or inflammatory disease; * ocular surgical history with in the last 3 months * SGOGREN SYNDROME

Design outcomes

Primary

Measure	Time frame	Description
Ocular Surface Disease Index (OSDI)	through study completion,an average of 6 months	normal value：\<13 abnormal value：≥ 13

Secondary

Measure	Time frame	Description
The concentrations of inflammatory cytokines such as IL-1、IL-6 and IL-8	through study completion,an average of 6 months	—
breakup time of tear film （BUT）	through study completion,an average of 6 months	normal value：\>10s abnormal value：≤ 10s
Corneal Fluorescein Stain(CFS)	through study completion,an average of 6 months	—
Eyelid ester discharge ability score	through study completion,an average of 6 months	—
Eyelid ester trait ratings	through study completion,an average of 6 months	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026